Soleno Therapeutics, Inc. Common Stock
SLNOSoleno Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and neglected diseases. The company's primary focus has been on treatments for neurological and metabolic disorders, aiming to address unmet medical needs through innovative drug development.
Company News
Soleno Therapeutics achieved its first profitable quarter with $66 million in revenue, attracting a significant $86.7 million investment from Connecticut-based fund Braidwell, which acquired 1.3 million shares in the biotechnology company.
Johnson Fistel is investigating potential securities law violations by Soleno Therapeutics after the company disclosed challenges with its drug VYKATâ„¢ XR launch, following a critical report by short seller Scorpion Capital that raised concerns about the product's safety and market potential.
Soleno Therapeutics, a medical device company, has entered into an agreement with Jefferies LLC to potentially sell up to $150 million of its common stock. The new funding option aims to bolster the company's financial flexibility and support its ongoing operations and strategic initiatives.
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc. (NASDAQ:AMZN) on Tuesday and Apple Inc. (NASDAQ:AAPL) on Thursday, a pivotal Federal Reserve Open Market Committee meeting on Wednesday, and the April’s ...
If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics, Inc. (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
